•
Jun 30, 2024

Natera Q2 2024 Earnings Report

Natera's second quarter financial results exceeded expectations, driven by strong performance in volume, revenue, and gross margin.

Key Takeaways

Natera reported a strong second quarter with total revenues of $413.4 million, a 58.1% increase compared to the second quarter of 2023. The company processed approximately 760,300 tests and reported a net loss of $37.5 million, or ($0.30) per diluted share.

Total revenues increased by 58.1% to $413.4 million compared to Q2 2023.

Product revenues increased by 59.3% to $411.4 million compared to Q2 2023.

Approximately 760,300 tests were processed in Q2 2024, including approximately 744,000 tests accessioned in the laboratory.

Net loss for the second quarter of 2024 was $37.5 million, or ($0.30) per diluted share.

Total Revenue
$413M
Previous year: $261M
+58.1%
EPS
-$0.3
Previous year: -$0.97
-69.1%
Tests Processed
760.3K
Previous year: 617.2K
+23.2%
Tests Accessioned
744K
Previous year: 599K
+24.2%
Total Tests Reported
725.2K
Previous year: 594.9K
+21.9%
Gross Profit
$243M
Previous year: $118M
+105.6%
Cash and Equivalents
$887M
Previous year: $736M
+20.5%
Free Cash Flow
-$7.69M
Previous year: -$87.4M
-91.2%
Total Assets
$1.52B
Previous year: $1.25B
+21.6%

Natera

Natera

Forward Guidance

Natera anticipates 2024 total revenue of $1.49 billion to $1.52 billion; 2024 gross margin to be approximately 54% to 56% of revenues; selling, general and administrative costs to be approximately $700 million to $750 million; research and development costs to be $350 million to $375 million; and net cash (outflow) inflow to be ($25) million to $25 million.